IONS 最新10-Q变化
将 IONS 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-07-29 与上一份 10-Q · 2026-04-29
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +21 | −18 | ~37 | 48 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 2 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 2 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 文字有新增/删除 | +2 | −4 | ~31 | 176 |
| 其他信息 | 文字有新增/删除 | +1 | −4 | ~1 | 3 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-07-29
SPINRAZA is an antisense medicine for the treatment of patients with spinal muscular atrophy, or SMA, a progressive, debilitating and often fatal genetic disease. Higher dose SPINRAZA was approved and launched in the U.S. and EU for the treatment of SMA. Higher dose SPINRAZA is also approved in Japa…
WAINUA (WAINZUA in Europe) is a once monthly, self-administered subcutaneous LICA medicine that is approved in numerous countries, including the U.S., EU, UK, Canada and China, for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, or ATTRv-PN, a debilitati…
Zilganersen is our investigational medicine for AxD. The FDA has granted Priority Review of zilganersen, with a Prescription Drug User Fee Act, or PDUFA, action date of September 22, 2026. The regulatory submission was based on the positive results from the Phase 3 portion of the pivotal study in ch…
Obudanersen is our medicine in development for AS. In July 2026, we completed enrollment of the Phase 3 study, REVEAL, which we designed to evaluate the efficacy and safety of obudanersen. In addition, we are continuing to conduct the open label Phase 1/2 study, HALOS, of obudanersen in patients wit…
Bepirovirsen is our medicine in development for chronic hepatitis B, or CHB. GSK is developing bepirovirsen. The FDA has granted Priority Review of bepirovirsen, with a PDUFA action date of October 26, 2026. In May 2026, GSK presented positive Phase 3 data for bepirovirsen at the 2026 European Assoc…
相对上期删除的文字 · 来源:10-Q · 2026-04-29
WAINUA (WAINZUA in Europe) is a once monthly, self-administered subcutaneous LICA medicine that is approved in numerous countries, including the U.S., EU, UK, Canada and China, for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, or ATTRv-PN, a debilitati…
SPINRAZA is an antisense medicine for the treatment of patients with spinal muscular atrophy, or SMA, a progressive, debilitating and often fatal genetic disease. Higher dose SPINRAZA was approved and launched in the U.S. and EU for the treatment of SMA. Higher dose SPINRAZA is also approved in Japa…
Olezarsen is our investigational medicine currently under regulatory review for sHTG, a second potential indication with a broad patient population. The FDA has granted Priority Review of olezarsen, with a Prescription Drug User Fee Act, or PDUFA, action date of June 30, 2026. In March 2026, the Eur…
Zilganersen is our investigational medicine for AxD. The FDA has granted Priority Review of zilganersen, with a PDUFA action date of September 22, 2026. The regulatory submission was based on the positive results from the Phase 3 portion of the pivotal study in children and adults with AxD. These re…
Obudanersen is our medicine in development for AS. In June 2025, we initiated the Phase 3 study, REVEAL, which we designed to evaluate the efficacy and safety of obudanersen. In addition, we are continuing to conduct the open label Phase 1/2 study, HALOS, of obudanersen in patients with AS designed …
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-07-29
● WAINUA faces competition from numerous competitors, including an oral product in markets outside the U.S.;
In December 2021, we entered into a collaborative agreement with AstraZeneca under which we granted AstraZeneca exclusive worldwide rights to develop and commercialize WAINUA, with the parties sharing responsibility and costs for development and U.S. commercialization activities, and AstraZeneca ass…
相对上期删除的文字 · 来源:10-Q · 2026-04-29
● WAINUA faces competition in ATTRv-PN from numerous competitors, including an oral product, and, if approved for ATTR-CM, would face competition from several commercial competitors, including an oral product, and could face competition from additional commercial competitors in the future;
We have entered into a collaborative arrangement with AstraZeneca to develop and commercialize WAINUA. Under the terms of the collaboration agreement, we and AstraZeneca are co-developing and co-commercializing WAINUA in the U.S. and AstraZeneca has the sole right to commercialize WAINUA in all othe…
In addition, a Joint Steering Committee, or JSC, having equal membership from us and AstraZeneca, and various subcommittees oversee and coordinate the development, manufacturing, commercialization and other exploitation activities for WAINUA in the U.S. by mutual agreement. If any subcommittee canno…
● AstraZeneca for the joint development and funding of WAINUA;
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-07-29
Shannon Devers Executive Vice President, Chief Human Resources Officer Termination April 14, 2026 X Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting The earlier to occur of (i) April 4, 2027, and (ii) Upon the execution of all instructions p…
相对上期删除的文字 · 来源:10-Q · 2026-04-29
Eric Swayze Executive Vice President, Research Termination March 6, 2026 X 177,770 The earlier to occur of (i) December 31, 2027, and (ii) Upon the execution of all instructions provided in the plan
Holly Kordasiewicz Executive Vice President, Chief Development Officer Adoption March 13, 2026 X Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting The earlier to occur of (i) May 31, 2027, and (ii) Upon the execution of all instructions provi…
Eric Swayze Executive Vice President, Research Adoption March 6, 2026 X Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting The earlier to occur of (i) December 31, 2030, and (ii) Upon the execution of all instructions provided in the plan
Frank Bennett Executive Vice President, Chief Scientific Officer Adoption March 31, 2026 X 67,386 The earlier to occur of (i) July 5, 2027, and (ii) Upon the execution of all instructions provided in the plan
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议